SAN FRANCISCO — Thirteen months after percutaneous left atrial appendage closure (LAAC), outcomes did not differ whether closure was performed using the Amulet (Abbott Cardiovascular) or the Watchman ...

First and only steerable delivery system designed to help seal the left atrial appendage (LAA) in people with atrial fibrillation who are at an increased risk of stroke Now available in the U.S., ...

Abbott Laboratories (NYSE:ABT) is one of the Best Dip Stocks to Buy According to Hedge Funds. On February 6, Abbott Laboratories (NYSE:ABT) released positive clinical trial results for its Amulet 360 ...

Abbott announced that the US Food and Drug Administration (FDA) approved the company's Amplatzer Amulet Left Atrial Appendage Occluder to treat people with atrial fibrillation (AFib) who are at risk ...

The noninferiority trial of patients at risk for both bleeding and stroke, in a surprise turn, found standard care to be ...

Abbott announced that the US Food and Drug Administration (FDA) has approved a new trial designed to assess its Amplatzer Amulet Left Atrial Appendage Occluder for people with atrial fibrillation (AF) ...

A team of specialists at Jacksonville, Fla.-based Baptist Health has become the first in the U.S.’ Southeast region to implant the Amplatzer Amulet Left Atrial Appendage Occluder. The device is meant ...

TCT 489: The Comparison of Tissue Characteristics of Restenosis After Coronary Interventions: Insights From a Histological Analysis After Directional Coronary Atherectomy Receive the the latest news, ...